Literature DB >> 7820138

Vascular considerations in postchemotherapy. Retroperitoneal lymph-node dissection: Part I--Vena cava.

J P Donohue1, J A Thornhill, R S Foster, R Bihrle.   

Abstract

A total of 42 patients underwent inferior vena cava resection (n = 40) or intraluminal tumor thrombectomy (n = 2) during retroperitoneal lymph-node dissection (RPLND) for bulky abdominal metastatic nonseminomatous germ-cell cancer (7% of all postchemotherapy RPLND cases). The three indications for caval resection included tumor clearance (38%), caval scar occlusion (14%), and caval tumor thrombus (48%). En bloc caval resection to achieve tumor clearance was justified by subsequent nodal pathology (cancer in 63% of specimens, teratoma in 31% specimens). Caval resection in the presence of scar occlusion was required de facto by virtue of its incorporation in the specimen. Caval resection or thrombectomy is indicated for intraluminal tumor thrombus because thrombus pathology (cancer, 35%; teratoma, 45%; fibrosis, 20%) reflected nodal pathology in 71% of cancer cases, 78% of teratoma cases, and 100% of fibrosis cases. The complications of caval resection were generally transitory. The 71% survival rate justifies this intensive surgical approach because these patients had exhausted all chemotherapeutic options.

Entities:  

Mesh:

Year:  1994        PMID: 7820138     DOI: 10.1007/bf00185668

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  13 in total

1.  Involvement of the caval vein lumen by a metastasis of a non-seminomatous testicular tumor.

Authors:  D Jacqmin; P Bertrand; J P Ansieau; P Dufour; C Bollack
Journal:  Eur Urol       Date:  1989       Impact factor: 20.096

2.  Metastatic pathways of nonseminomatous germ cell tumors.

Authors:  J P Donohue
Journal:  Semin Urol       Date:  1984-11

3.  Obstruction of the inferior vena cava by seminoma.

Authors:  W F Rogers; P W Ralls; W D Boswell
Journal:  J Urol       Date:  1980-11       Impact factor: 7.450

4.  Risk/benefit of treating retroperitoneal teratoid bulky tumors.

Authors:  N Jaeger; L Weissbach; J H Hartlapp; W Vahlensieck
Journal:  Urology       Date:  1989-07       Impact factor: 2.649

Review 5.  Disseminated testicular cancer: current chemotherapy strategies.

Authors:  S D Williams; P J Loehrer; C R Nichols; B J Roth; L H Einhorn
Journal:  Semin Oncol       Date:  1989-08       Impact factor: 4.929

6.  Autopsy findings in 154 patients with germ cell tumors of the testis.

Authors:  J J Bredael; D Vugrin; W F Whitmore
Journal:  Cancer       Date:  1982-08-01       Impact factor: 6.860

7.  En bloc resection of inferior vena cava in cytoreductive surgery for bulky retroperitoneal metastatic testicular cancer.

Authors:  D J Mathisen; N Javadpour
Journal:  Urology       Date:  1980-07       Impact factor: 2.649

8.  A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors.

Authors:  G J Bosl; N L Geller; D Bajorin; S P Leitner; A Yagoda; R B Golbey; H Scher; N J Vogelzang; J Auman; R Carey
Journal:  J Clin Oncol       Date:  1988-08       Impact factor: 44.544

9.  Unusual thoracoabdominal sites of metastases in testicular tumors.

Authors:  J E Husband; E A Bellamy
Journal:  AJR Am J Roentgenol       Date:  1985-12       Impact factor: 3.959

10.  Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer.

Authors:  L H Einhorn; J Donohue
Journal:  Ann Intern Med       Date:  1977-09       Impact factor: 25.391

View more
  1 in total

Review 1.  Inferior vena cava prosthetic replacement in a patient with horseshoe kidney and metastatic testicular tumor: technical considerations and review of the literature.

Authors:  Pietro Rispoli; Paolo Destefanis; Paolo Garneri; Gianfranco Varetto; Beatrice Lillaz; Claudio Castagno; Patrizia Lista; Libero Ciuffreda; Dario Fontana
Journal:  BMC Urol       Date:  2014-05-22       Impact factor: 2.264

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.